Skip to main content
. Author manuscript; available in PMC: 2017 Jul 4.
Published in final edited form as: Diabetes Metab Res Rev. 2014 Mar;30(3):191–200. doi: 10.1002/dmrr.2466

Table 2.

Trabecular bone analyses of the femoral distal metaphyses from the diabetic MKR mice after 8 weeks of treatment

Vehicle (n = 20) MK-0626 (n = 13) Pioglitazone (n = 12) Alendronate (n = 7)
BV/TV (%) 7.16 ± 1.7 6.58 ± 1.60 8.7 ± 1.64 10.79 ± 1.07 *
Tb.Th, μm 0.043 ± 0.002 0.044 ± 0.002 0.044 ± 0.000 0.041 ± 0.001
Tb.N/mm 1.64 ± 0.379 1.45 ± 0.32 1.96 ± 0.34 2.59 ± 0.26 *
Tb.Sp, μm 0.25 ± 0.034 0.28 ± 0.027 0.24 ± 0.015 0.19 ± 0.014*

BV/TV, %, bone volume per total volume; Tb.Th, μm, trabecular thickness; Tb.N, mm−1, trabecular number; Tb.Sp, μm, trabecular separation. Results are expressed as mean values ± SEM.

*

p value <0.05 between MKR vehicle and MKR alendronate-treated groups.